Archived Monthly Oncology Tumor Boards: Management of Recurrent/Metastatic Cervical Cancer and Neuroendocrine Carcinoma of the Cervix |
1.00 |
12/05/2023 - 12:00am to 12/05/2024 - 12:00am |
Recorded Presentations from the NCCN 2023 Annual Congress: Hematologic Malignancies™ |
|
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Revolutionizing Hematologic Cancer Treatment: The Promise of Bispecific T-Cell Engagers |
1.00 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies |
1.00 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Adult Acute Lymphocytic Leukemia: Strategies for Selection of Consolidation Therapy |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Acute Myeloid Leukemia: Selecting Induction Therapy Based on Biological Disease Factors |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Case Studies in the Management of Leukemia |
0.75 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Navigating Change: Best Practices for Integrating WHO/ICC Classification Systems in the Management of Hematologic Malignancies |
1.00 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Management of Newly Diagnosed Multiple Myeloma Based on Risk Stratification |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Incorporating Immunotherapeutic Strategies in the Management of Relapsed/Refractory Multiple Myeloma |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Tackling Inequities in Multiple Myeloma: Practical Steps for Improving Access and Quality of Care |
1.00 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Advances in the Management of Classical Hodgkin Lymphoma |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Perioperative Management of Anticoagulation and Antithrombotic Therapy |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Updates in the Management of Mantle Cell Lymphoma: Is There Still a Role for Transplant? |
1.00 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |